Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;16(12):2411-2412.
doi: 10.4103/1673-5374.313042.

Neurovascular ageing: transcriptomic readout and implications on therapeutic targeting in Alzheimer's disease

Zhongqi Li  1 , Bonaventure Ip  2 , Vincent C T Mok  3 , Ho Ko  4
Affiliations
Review

Neurovascular ageing: transcriptomic readout and implications on therapeutic targeting in Alzheimer's disease

Zhongqi Li et al. Neural Regen Res. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Age-related neurovascular dysfunction in neurodegeneration and zonation-dependent endothelial alterations in the aged mouse brain. (A) Illustration of the current understandings on the relationship between age-related neurovascular dysfunction and neurodegeneration. (B) Functional implications of the zonation-dependent ageing-associated transcriptomic changes in the endothelial cell subtypes, which can be partially reversed by GLP-1RA treatment. Symbol in A and B: Δ refers to “altered". AD: Alzheimer's disease; EC: endothelial cell; GLP-1RA: glucagon-like peptide-1 receptor agonist; GLUT1: glucose transporter 1; GWAS: genome-wide association; MFSD2A: major facilitator superfamily domain-containing 2A; TGF: transforming growth factor; VEGF: vascular endothelial growth factor.
See this image and copyright information in PMC

References

    1. Andreone BJ, Chow BW, Tata A, Lacoste B, Ben-Zvi A, Bullock K, Deik AA, Ginty DD, Clish CB, Gu C. Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. Neuron. 2017;94:581–594. - PMC - PubMed
    1. Brauer R, Wei L, Ma T, Athauda D, Girges C, Vijiaratnam N, Auld G, Whittlesea C, Wong I, Foltynie T. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. Brain. 2020;143:3067–3076. - PMC - PubMed
    1. Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, García-Pérez LE, Lakshmanan M, Bethel A, Xavier D, Probstfield J, Riddle MC, Rydén L, Atisso CM, Hall S, Rao-Melacini P, Basile J, Cushman WC, Franek E, Keltai M, Lanas F, Leiter LA, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020;19:582–590. - PubMed
    1. Hur JY, Frost GR, Wu X, Crump C, Pan SJ, Wong E, Barros M, Li T, Nie P, Zhai Y, Wang JC, Tcw J, Guo L, McKenzie A, Ming C, Zhou X, Wang M, Sagi Y, Renton AE, Esposito BT, et al. The innate immunity protein IFITM3 modulates gamma-secretase in Alzheimer's disease. Nature. 2020;586:735–740. - PMC - PubMed
    1. Korte N, Nortley R, Attwell D. Cerebral blood flow decrease as an early pathological mechanism in Alzheimer's disease. Acta Neuropathol. 2020;140:793–810. - PMC - PubMed